James Kihara Acadia Pharmaceuticals Inc (ACAD) insider trading activity

James Kihara is PRINCIPAL ACCOUNTING OFFICER of ACADIA PHARMACEUTICALS INC. Currently has a direct ownership of 22,257 shares of ACAD, which is worth approximately $330,739. The most recent transaction as insider was on Apr 08, 2025, when has been sold 1,028 shares (Common Stock) at a price of $14.82 per share, resulting in proceeds of $15,234. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 22.3K

12.05% 3M change

69.9% 12M change

Total Value Held $330,739

James Kihara Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 08 2025	SELL Open market or private sale	$15,234 $14.82 p/Share	1,028 Reduced 4.41%	22,257 Common Stock
Apr 05 2025	BUY Exercise of conversion of derivative security	-	2,010 Added 7.95%	23,285 Common Stock
Mar 26 2025	SELL Open market or private sale	$18,669 $17.05 p/Share	1,095 Reduced 4.89%	21,275 Common Stock
Mar 25 2025	BUY Exercise of conversion of derivative security	-	2,142 Added 8.74%	22,370 Common Stock
Feb 24 2025	SELL Open market or private sale	$9,481 $19.96 p/Share	475 Reduced 2.29%	20,228 Common Stock
Feb 23 2025	BUY Exercise of conversion of derivative security	-	840 Added 3.9%	20,703 Common Stock
Nov 19 2024	SELL Open market or private sale	$68,467 $16.81 p/Share	4,073 Reduced 17.02%	19,863 Common Stock
Nov 17 2024	BUY Exercise of conversion of derivative security	-	7,930 Added 24.89%	23,936 Common Stock
May 02 2024	SELL Open market or private sale	$22,462 $16.94 p/Share	1,326 Reduced 8.45%	14,370 Common Stock
May 01 2024	BUY Exercise of conversion of derivative security	-	2,596 Added 14.19%	15,696 Common Stock
Apr 08 2024	SELL Open market or private sale	$31,987 $17.87 p/Share	1,790 Reduced 12.02%	13,100 Common Stock
Apr 07 2024	BUY Exercise of conversion of derivative security	-	1,489 Added 9.09%	14,890 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	2,010 Added 13.04%	13,401 Common Stock
Feb 26 2024	SELL Open market or private sale	$11,693 $24.67 p/Share	474 Reduced 3.99%	11,391 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	840 Added 6.61%	11,865 Common Stock
Dec 15 2023	SELL Open market or private sale	$56,600 $28.3 p/Share	2,000 Reduced 15.36%	11,025 Common Stock
Nov 20 2023	SELL Open market or private sale	$44,940 $22.64 p/Share	1,985 Reduced 13.22%	13,025 Common Stock
Nov 17 2023	BUY Exercise of conversion of derivative security	-	3,964 Added 20.89%	15,010 Common Stock
Sep 15 2023	SELL Open market or private sale	$51,760 $25.88 p/Share	2,000 Reduced 15.65%	10,778 Common Stock
Jun 15 2023	SELL Open market or private sale	$48,300 $24.15 p/Share	2,000 Reduced 17.95%	9,144 Common Stock
May 17 2023	SELL Open market or private sale	$133,807 $22.5 p/Share	5,947 Reduced 34.8%	11,144 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	-	11,894 Added 41.04%	17,091 Common Stock
Apr 10 2023	SELL Open market or private sale	$9,487 $18.14 p/Share	523 Reduced 9.14%	5,197 Common Stock
Apr 07 2023	BUY Exercise of conversion of derivative security	-	1,489 Added 20.65%	5,720 Common Stock
Apr 06 2023	SELL Open market or private sale	$12,730 $18.16 p/Share	701 Reduced 14.21%	4,231 Common Stock

James Kihara

PRINCIPAL ACCOUNTING OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Value

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD

Account